非典型慢性髓系白血病与骨髓增生异常/骨髓增殖性肿瘤不能分类:2023年诊断、风险分层与管理更新
本文综述非典型慢性髓系白血病(aCML)与骨髓增生异常/骨髓增殖性肿瘤不能分类(MDS/MPN-NOS)的诊断、突变与核型、风险分层和治疗。aCML现被ICC命名为aCML、WHO第五版命名为伴中性粒细胞增多的MDS/MPN;Mayo Clinic aCML模型按年龄>67岁、血红蛋白<10 g/dl和TET2突变分层,低危与高危中位生存分别为18和7个月;去甲基化药物反应欠佳,异基因造血干细胞移植是唯一治愈手段但并发症与死亡率高。
要点
- aCML与MDS/MPN-NOS为MDS/MPN重叠肿瘤,表现为白细胞增多、无单核细胞增多和嗜酸性粒细胞增多,血和骨髓原始细胞<20%。
- aCML由ICC命名为aCML、WHO第五版命名为伴中性粒细胞增多的MDS/MPN,特征为发育异常中性粒细胞增多伴未成熟髓系细胞≥10%。
- Mayo Clinic aCML模型将年龄>67岁、血红蛋白<10 g/dl和TET2突变分别计分,低危(0-1分)与高危(>2分)中位生存分别为18和7个月。
核心结论
- aCML与MDS/MPN-NOS是MDS/MPN重叠肿瘤,诊断需排除单核细胞增多、嗜酸性粒细胞增多及原始细胞<20%。
- aCML被ICC命名为aCML、WHO第五版命名为伴中性粒细胞增多的MDS/MPN。
- 去甲基化药物在两类疾病中反应率欠佳,异基因造血干细胞移植是唯一治愈策略但并发症与死亡率高。
研究设计与样本
- 本文为2023年更新综述,汇总aCML与MDS/MPN-NOS的诊断、风险分层与管理。
主要发现
- 两类疾病中40-50%患者可见细胞遗传学异常。
- aCML常见体细胞突变包括ASXL1、SETBP1、ETNK1和EZH2。
- MDS/MPN-NOS可按突变谱分为CMML样、MDS/MPN-RS-T样、aCML样、TP35突变和「其他」。
- Mayo Clinic aCML模型低危(0-1分)与高危(>2分)中位生存分别为18和7个月。
- MDS/MPN-NOS传统上使用IPSS和IPSS-R等MDS风险模型进行风险分层。
关键数值与推荐
- aCML特征为发育异常中性粒细胞增多,未成熟髓系细胞占白细胞计数≥10%,伴显著粒细胞发育异常。
- MDS/MPN-NOS指不符合CMML、MDS/MPN-RS-T和aCML等既定类别标准的MDS/MPN重叠肿瘤。
- Mayo Clinic aCML模型风险因素为年龄>67岁、血红蛋白<10 g/dl和存在TET2突变。
临床怎么用
- 白细胞增多和贫血按较低危MPN和MDS管理。
- 去甲基化药物已用于两类疾病,但反应率欠佳。
- 异基因造血干细胞移植仍是唯一治愈策略,但并发症与死亡率高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Atypical chronic myeloid leukemia (aCML) and myelodysplastic/myeloproliferative (MDS/MPN) neoplasms, not otherwise specified (NOS), are MDS/MPN overlap neoplasms characterized by leukocytosis, in the absence of monocytosis and eosinophilia, with <20% blasts in the blood and bone marrow. DIAGNOSIS: aCML, previously known as aCML, BCR::ABL1 negative, was renamed as aCML by the ICC classification, and as MDS/MPN with neutrophilia by the 5th edition of the WHO classification. This entity is characterized by dysplastic neutrophilia with immature myeloid cells comprising ≥10% of the white blood cell count, with prominent dysgranulopoiesis. MDS/MPN-NOS consists of MDS/MPN overlap neoplasms not meeting criteria for defined categories such as chronic myelomonocytic leukemia (CMML), MDS/MPN-ring sideroblasts-thrombocytosis (MDS/MPN-RS-T), and aCML. MUTATIONS AND KARYOTYPE: Cytogenetic abnormalities are seen in 40-50% of patients in both categories. In aCML, somatic mutations commonly encountered include ASXL1, SETBP1, ETNK1, and EZH2 whereas MDS/MPN-NOS can be further stratified by mutational profiles into CMML-like, MDS/MPN-RS-T-like, aCML-like, TP35-mutated, and "others", respectively. RISK STRATIFICATION: The Mayo Clinic aCML model stratifies patients based on age >67 years, hemoglobin <10 g/dl, and the presence of TET2 mutations into low-risk (0-1 points) and high-risk (>2 points) groups, with median survivals of 18 and 7 months, respectively. MDS/MPN-NOS patients have traditionally been risk stratified using MDS risk models such as IPSS and IPSS-R. TREATMENT: Leukocytosis and anemia are managed like lower risk MPN and MDS. DNMT inhibitors have been used in both entities with suboptimal response rates. Allogeneic stem cell transplant remains the only curative strategy but is associated with high morbidity and mortality.
引用
- Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023. PMID: 36601682. doi:10.1002/ajh.26828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。